Select RWE in adult patients with NVAF
RWE should be reviewed in the context of RCT data. All RWE resources below also include data from the ARISTOTLE clinical trial.
Dawwas NVAF 2025 analysis
Published in the Journal of Thrombosis and Haemostasis
An independently funded, retrospective, observational real-world database analysis comparing the effectiveness and safety of ELIQUIS vs XARELTO® (rivaroxaban) in patients with NVAF aged 65 years or older.5
Sentinel* Database analysis
Available at sentinelinitiative.org
An independently funded, retrospective, observational real-world database analysis comparing bleeding and stroke risks of ELIQUIS vs XARELTO® (rivaroxaban) in patients younger than 65 years with NVAF.6,7
Analysis should not be construed as an actual or implied endorsement by the FDA of any of the products discussed.
*FDA Sentinel is a national safety surveillance system for medical products that is primarily composed of aggregated electronic healthcare and administrative claims data.7
ATHENS analysis
Published in the Journal of Clinical Medicine
A retrospective, observational real-world database analysis evaluating the outcomes of ELIQUIS compared to XARELTO® (rivaroxaban) in patients with NVAF.8
Ray et al analysis
Published in the Journal of the American Medical Association (JAMA)
The largest independently funded, retrospective, observational real-world database analysis evaluating the association of ELIQUIS vs XARELTO® (rivaroxaban) with major ischemic or hemorrhagic events in Medicare beneficiaries with NVAF (N=581,451).9
Fralick et al analysis
Published in the Annals of Internal Medicine
An independently funded, retrospective, observational real-world database analysis on the effectiveness and safety of ELIQUIS compared to XARELTO® (rivaroxaban) for patients with NVAF in routine practice.10
NVAF Hospital Readmissions analysis
Published in the Journal of Drug Assessment
A retrospective, observational real-world database analysis comparing stroke-related readmissions among hospitalized patients with NVAF treated with OACs in the US.11
There are currently no results from clinical trials comparing ELIQUIS to XARELTO® (rivaroxaban) for stroke risk reduction in NVAF.12, 13
Select RWE in adult patients with DVT/PE
RWE should be reviewed in the context of RCT data. All RWE resources below also include data from the AMPLIFY clinical trial.
Jin et al analysis
Published in Thrombosis Research
The largest independently funded, retrospective, observational real-world database analysis comparing the effectiveness and safety of ELIQUIS vs XARELTO® (rivaroxaban) for commercially insured and Medicare Advantage patients with DVT/PE (N=41,830).15
Dawwas et al analysis
Published in the Annals of Internal Medicine
An independently funded, retrospective cohort, real-world database analysis on the risk of recurrent VTE and bleeding with ELIQUIS compared with XARELTO® (rivaroxaban).16
VTE Hospital Readmissions analysis
Published in Hospital Practice
A retrospective real-world data analysis on the ED: hospital readmissions (inpatient or ED) of patients treated with ELIQUIS or warfarin.17
Other studies (including RCT and RWD analyses) in adult patients comparing ELIQUIS with other DOACs, which may have used different methods, populations, and outcome definitions, have shown different findings.14-16,18-25
DOAC=direct oral anticoagulant; DVT=deep vein thrombosis; ED=emergency department; JAMA=Journal of the American Medical Association; NVAF=nonvalvular atrial fibrillation; OAC=oral anticoagulant; PE=pulmonary embolism; RCT=randomized clinical trial; RWD=real-world data; RWE=real-world evidence; VTE=venous thromboembolism.
XARELTO® (rivaroxaban) is a registered trademark of Bayer Aktiengesellschaft.
References
432-US-2500273 09/25